Skip to Main Content

Paper Details

Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab.
Lancet Oncol
20
2022
Author NameAffiliation
Stefan SleijferErasmus University Medical Center
  • 1 - 1

Datasets

Release 1.2